Threats to the value of Health Technology Assessment: Qualitative evidence from Canada and Poland

被引:7
作者
Wranik, Wieslawa Dominika [1 ,2 ,3 ]
Zielinska, Dorota Anna [3 ,4 ]
Gambold, Lies [5 ,6 ]
Sevgur, Serperi [5 ]
机构
[1] Dalhousie Univ, Fac Management, Sch Publ Adm, 6100 Univ Ave, Halifax, NS B3H 4R2, Canada
[2] Dalhousie Univ, Fac Med, Dept Community Hlth & Epidemiol, Halifax, NS, Canada
[3] SGH Warsaw Sch Econ, Decis Anal Support Unit, Ul Madalinskiego 6-8, PL-02513 Warsaw, Poland
[4] Univ Warsaw, Inst Sociol, Ul Karowa 18, PL-00324 Warsaw, Poland
[5] Dalhousie Univ, Dept Sociol & Social Anthropol, 6135 Univ Ave, Halifax, NS B3H 4R2, Canada
[6] Dalhousie Univ, Jean Monnet European Union, Ctr Excellence, 6299 South St, Halifax, NS B3H 4R2, Canada
关键词
REIMBURSEMENT DECISION-MAKING; DISCRETE-CHOICE EXPERIMENT; REAL-WORLD DATA; DRUG REIMBURSEMENT; FUNDING DECISIONS; CANCER DRUGS; RESOURCE-ALLOCATION; RECOMMENDATIONS; IMPACT; PERSPECTIVES;
D O I
10.1016/j.healthpol.2018.12.001
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Health Technology Assessment is used to support the process of drug appraisal and reimbursement decisions in a variety of health systems. Examples can be found in mature Western countries, such as Canada, and in emerging economies of Central and Eastern Europe, such as Poland. The value of HTA in the process is influenced by the evidence used and the stakeholders involved. Methods: Qualitative interviews with 29 members of two appraisal committees were held in Canada and Poland between July 2017 and March 2018. An a priori thematic framework was applied and supplemented with emergent themes. Results: We report on the results of a core emergent theme - threats identified by respondents to the value of HTA in the formulary process. We classified these into internal threats that arise due to undue influence on the individuals involved in appraisal, and external threats that arise due to undue influence on the production of evidence. Discussion: Findings align with previous evidence regarding political and corporate pressures on the process, and a perception of declining quality of evidence. We contribute to the discussion by highlighting the importance of motivation of experts involved in the appraisal process. Conclusions: The recognition of internal and external threats lays the groundwork for a discussion of policies used to mitigate them. We offer suggestions about potential policy responses. (C) 2018 The Authors. Published by Elsevier B.V.
引用
收藏
页码:191 / 202
页数:12
相关论文
共 56 条
[1]  
[Anonymous], 2009, WORLD BANK POLICY RE
[2]   Drug formulary decision-making in two regional health authorities in British Columbia, Canada [J].
Armstrong, Kristy ;
Mitton, Craig ;
Carleton, Bruce ;
Shoveller, Jean .
HEALTH POLICY, 2008, 88 (2-3) :308-316
[3]   Systems for grading the quality of evidence and the strength of recommendations -: I:: Critical appraisal of existing approaches The GRADE Working Group -: art. no. 38 [J].
Atkins, D ;
Eccles, M ;
Flottorp, S ;
Guyatt, GH ;
Henry, D ;
Hill, S ;
Liberati, A ;
O'Connell, D ;
Oxman, AD ;
Phillips, B ;
Schünemann, H ;
Edejer, TTT ;
Vist, GE ;
Williams, JW .
BMC HEALTH SERVICES RESEARCH, 2004, 4 (1)
[4]   Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea [J].
Bae, Green ;
Bae, Eun Young ;
Bae, SeungJin .
HEALTH POLICY, 2015, 119 (05) :577-587
[5]   Seeing the nice side of cost-effectiveness analysis: A qualitative investigation of the use of CEA in nice technology appraisals [J].
Bryan, Stirling ;
Williams, Iestyn ;
McIver, Shirley .
HEALTH ECONOMICS, 2007, 16 (02) :179-193
[6]   Decision making by NICE: examining the influences of evidence, process and context [J].
Cerri, Karin H. ;
Knapp, Martin ;
Fernandez, Jose-Luis .
HEALTH ECONOMICS POLICY AND LAW, 2014, 9 (02) :119-141
[7]  
Chafe Roger, 2011, Healthc Policy, V6, P27
[8]   Which Factors Enhance Positive Drug Reimbursement Recommendation in Scotland? A Retrospective Analysis 2006-2013 [J].
Charokopou, Mata ;
Majer, Istvan M. ;
de Raad, Johan ;
Broekhuizen, Stefan ;
Postma, Maarten ;
Heeg, Bart .
VALUE IN HEALTH, 2015, 18 (02) :284-291
[9]   International variability in the reimbursement of cancer drugs by publically funded drug programs [J].
Cheema, P. K. ;
Gavura, S. ;
Migus, M. ;
Godman, B. ;
Yeung, L. ;
Trudeau, M. E. .
CURRENT ONCOLOGY, 2012, 19 (03) :E165-E176
[10]   Do economic evaluations have a role in decision-making in Medicine Management Committees? A qualitative study [J].
Chen, Li-Chia ;
Ashcroft, Darren M. ;
Elliott, Rachel A. .
PHARMACY WORLD & SCIENCE, 2007, 29 (06) :661-670